You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Immune Checkpoint Inhibitors Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 36030 million by 2027, from US$ 14730 million in 2020, at a CAGR of 16.1% during 2021-2027.
In terms of production side, this report researches the Immune Checkpoint Inhibitors production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Immune Checkpoint Inhibitors by regions (countries) and by Application.
The global Immune Checkpoint Inhibitors market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Immune Checkpoint Inhibitors market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Immune Checkpoint Inhibitors markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Immune Checkpoint Inhibitors market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Immune Checkpoint Inhibitors market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Immune Checkpoint Inhibitors market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Immune Checkpoint Inhibitors market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Immune Checkpoint Inhibitors market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Immune Checkpoint Inhibitors market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Immune Checkpoint Inhibitors market by each application segment for the same period.
This report includes the following manufacturers:
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Market Segment by Type
PD-1/PD-L1
CTLA-4
Market Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Research Methodology
To compile the detailed study of the global Immune Checkpoint Inhibitors market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Immune Checkpoint Inhibitors market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Immune Checkpoint Inhibitors market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Market Segment by Application
1.3.1 Global Immune Checkpoint Inhibitors Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 Study Objectives
1.5 Years Considered

2 Market Perspective
2.1 Global Immune Checkpoint Inhibitors Market Size (2016-2027)
2.1.1 Global Immune Checkpoint Inhibitors Revenue (2016-2027)
2.1.2 Global Immune Checkpoint Inhibitors Sales (2016-2027)
2.2 Global Immune Checkpoint Inhibitors Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Immune Checkpoint Inhibitors Sales by Regions (2016-2021)
2.2.2 Global Immune Checkpoint Inhibitors Revenue by Regions (2016-2021)
2.3 Global Immune Checkpoint Inhibitors Market Size Forecast by Region
2.3.1 Global Immune Checkpoint Inhibitors Sales Forecast by Region (2022-2027)
2.3.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2022-2027)
2.4 Global Top Immune Checkpoint Inhibitors Regions (Countries) Ranking by Market Size
2.5 Immune Checkpoint Inhibitors Industry Trends
2.5.1 Immune Checkpoint Inhibitors Market Trends
2.5.2 Immune Checkpoint Inhibitors Market Drivers
2.5.3 Immune Checkpoint Inhibitors Market Challenges
2.5.4 Immune Checkpoint Inhibitors Market Restraints

3 Competitive Landscape by Manufacturers
3.1 Global Top Immune Checkpoint Inhibitors Manufacturers by Sales (2016-2021)
3.1.1 Global Immune Checkpoint Inhibitors Sales by Manufacturers (2016-2021)
3.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Immune Checkpoint Inhibitors Sales in 2020
3.2 Global Top Manufacturers Immune Checkpoint Inhibitors by Revenue
3.2.1 Global Immune Checkpoint Inhibitors Revenue by Manufacturers (2016-2021)
3.2.2 Top Immune Checkpoint Inhibitors Manufacturers Covered: Ranking by Revenue
3.2.3 Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Immune Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2020)
3.4 Global Immune Checkpoint Inhibitors Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Immune Checkpoint Inhibitors Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Immune Checkpoint Inhibitors Market
3.7 Key Manufacturers Immune Checkpoint Inhibitors Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Global Immune Checkpoint Inhibitors Market Size by Type
4.1 Global Immune Checkpoint Inhibitors Historic Market Review by Type (2016-2021)
4.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
4.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
4.1.3 Immune Checkpoint Inhibitors Price by Type (2016-2021)
4.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2022-2027)
4.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2022-2027)
4.2.3 Immune Checkpoint Inhibitors Price Forecast by Type (2022-2027)

5 Global Immune Checkpoint Inhibitors Market Size by Application
5.1 Global Immune Checkpoint Inhibitors Historic Market Review by Application (2016-2021)
5.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
5.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
5.1.3 Immune Checkpoint Inhibitors Price by Application (2016-2021)
5.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2022-2027)
5.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2022-2027)
5.2.3 Immune Checkpoint Inhibitors Price Forecast by Application (2022-2027)

6 North America
6.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Company
6.1.1 North America Immune Checkpoint Inhibitors Sales by Company (2016-2027)
6.1.2 North America Immune Checkpoint Inhibitors Revenue by Company (2016-2027)
6.2 North America Immune Checkpoint Inhibitors Market Size by Type (2016-2027)
6.2.1 North America Immune Checkpoint Inhibitors Sales by Type (2016-2027)
6.2.2 North America Immune Checkpoint Inhibitors Revenue by Type (2016-2027)
6.3 North America Immune Checkpoint Inhibitors Market Size by Application (2016-2027)
6.3.1 North America Immune Checkpoint Inhibitors Sales by Application (2016-2027)
6.3.2 North America Immune Checkpoint Inhibitors Revenue by Application (2016-2027)
6.4 North America Immune Checkpoint Inhibitors Market Size by Country
6.4.1 North America Immune Checkpoint Inhibitors Sales by Country (2016-2027)
6.4.2 North America Immune Checkpoint Inhibitors Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Immune Checkpoint Inhibitors Sales Breakdown by Company
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Company (2016-2027)
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Company (2016-2027)
7.2 Europe Immune Checkpoint Inhibitors Market Size by Type (2016-2027)
7.2.1 Europe Immune Checkpoint Inhibitors Sales by Type (2016-2027)
7.2.2 Europe Immune Checkpoint Inhibitors Revenue by Type (2016-2027)
7.3 Europe Immune Checkpoint Inhibitors Market Size by Application (2016-2027)
7.3.1 Europe Immune Checkpoint Inhibitors Sales by Application (2016-2027)
7.3.2 Europe Immune Checkpoint Inhibitors Revenue by Application (2016-2027)
7.4 Europe Immune Checkpoint Inhibitors Market Size by Country
7.4.1 Europe Immune Checkpoint Inhibitors Sales by Country (2016-2027)
7.4.2 Europe Immune Checkpoint Inhibitors Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Immune Checkpoint Inhibitors Sales Breakdown by Company
8.1.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Company (2016-2027)
8.1.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Company (2016-2027)
8.2 Asia Pacific Immune Checkpoint Inhibitors Market Size by Type (2016-2027)
8.2.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Type (2016-2027)
8.2.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Type (2016-2027)
8.3 Asia Pacific Immune Checkpoint Inhibitors Market Size by Application (2016-2027)
8.3.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Application (2016-2027)
8.3.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Application (2016-2027)
8.4 Asia Pacific Immune Checkpoint Inhibitors Market Size by Regions
8.4.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Regions
8.4.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Immune Checkpoint Inhibitors Sales Breakdown by Company
9.1.1 Latin America Immune Checkpoint Inhibitors Sales by Company (2016-2027)
9.1.2 Latin America Immune Checkpoint Inhibitors Revenue by Company (2016-2027)
9.2 Latin America Immune Checkpoint Inhibitors Market Size by Type (2016-2027)
9.2.1 Latin America Immune Checkpoint Inhibitors Sales by Type (2016-2027)
9.2.2 Latin America Immune Checkpoint Inhibitors Revenue by Type (2016-2027)
9.3 Latin America Immune Checkpoint Inhibitors Market Size by Application (2016-2027)
9.3.1 Latin America Immune Checkpoint Inhibitors Sales by Application (2016-2027)
9.3.2 Latin America Immune Checkpoint Inhibitors Revenue by Application (2016-2027)
9.4 Latin America Immune Checkpoint Inhibitors Market Size by Country
9.4.1 Latin America Immune Checkpoint Inhibitors Sales by Country (2016-2027)
9.4.2 Latin America Immune Checkpoint Inhibitors Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Immune Checkpoint Inhibitors Sales Breakdown by Company
10.1.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Company (2016-2027)
10.1.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Company (2016-2027)
10.2 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2016-2027)
10.2.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Type (2016-2027)
10.3 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2016-2027)
10.3.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Application (2016-2027)
10.4 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Country
10.4.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2016-2027)
10.4.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E

11 Company Profiles
11.1 Bristol Myer Squibb
11.1.1 Bristol Myer Squibb Corporation Information
11.1.2 Bristol Myer Squibb Overview
11.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products and Services
11.1.5 Bristol Myer Squibb Immune Checkpoint Inhibitors SWOT Analysis
11.1.6 Bristol Myer Squibb Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 AstraZeneca Immune Checkpoint Inhibitors Products and Services
11.2.5 AstraZeneca Immune Checkpoint Inhibitors SWOT Analysis
11.2.6 AstraZeneca Recent Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Overview
11.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Merck & Co. Immune Checkpoint Inhibitors Products and Services
11.3.5 Merck & Co. Immune Checkpoint Inhibitors SWOT Analysis
11.3.6 Merck & Co. Recent Developments
11.4 Roche / Genentech
11.4.1 Roche / Genentech Corporation Information
11.4.2 Roche / Genentech Overview
11.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products and Services
11.4.5 Roche / Genentech Immune Checkpoint Inhibitors SWOT Analysis
11.4.6 Roche / Genentech Recent Developments
11.5 Incyte Corporation
11.5.1 Incyte Corporation Corporation Information
11.5.2 Incyte Corporation Overview
11.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products and Services
11.5.5 Incyte Corporation Immune Checkpoint Inhibitors SWOT Analysis
11.5.6 Incyte Corporation Recent Developments
11.6 NewLink Genetics
11.6.1 NewLink Genetics Corporation Information
11.6.2 NewLink Genetics Overview
11.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products and Services
11.6.5 NewLink Genetics Immune Checkpoint Inhibitors SWOT Analysis
11.6.6 NewLink Genetics Recent Developments
11.7 ArGEN-X
11.7.1 ArGEN-X Corporation Information
11.7.2 ArGEN-X Overview
11.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 ArGEN-X Immune Checkpoint Inhibitors Products and Services
11.7.5 ArGEN-X Immune Checkpoint Inhibitors SWOT Analysis
11.7.6 ArGEN-X Recent Developments
11.8 Seattle Genetics
11.8.1 Seattle Genetics Corporation Information
11.8.2 Seattle Genetics Overview
11.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products and Services
11.8.5 Seattle Genetics Immune Checkpoint Inhibitors SWOT Analysis
11.8.6 Seattle Genetics Recent Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Overview
11.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 Pfizer Immune Checkpoint Inhibitors Products and Services
11.9.5 Pfizer Immune Checkpoint Inhibitors SWOT Analysis
11.9.6 Pfizer Recent Developments
11.10 MacroGenics
11.10.1 MacroGenics Corporation Information
11.10.2 MacroGenics Overview
11.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.10.4 MacroGenics Immune Checkpoint Inhibitors Products and Services
11.10.5 MacroGenics Immune Checkpoint Inhibitors SWOT Analysis
11.10.6 MacroGenics Recent Developments
11.11 Celldex Therapeutics
11.11.1 Celldex Therapeutics Corporation Information
11.11.2 Celldex Therapeutics Overview
11.11.3 Celldex Therapeutics Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.11.4 Celldex Therapeutics Immune Checkpoint Inhibitors Products and Services
11.11.5 Celldex Therapeutics Recent Developments
11.12 CureTech
11.12.1 CureTech Corporation Information
11.12.2 CureTech Overview
11.12.3 CureTech Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.12.4 CureTech Immune Checkpoint Inhibitors Products and Services
11.12.5 CureTech Recent Developments
11.13 Immutep
11.13.1 Immutep Corporation Information
11.13.2 Immutep Overview
11.13.3 Immutep Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.13.4 Immutep Immune Checkpoint Inhibitors Products and Services
11.13.5 Immutep Recent Developments
11.14 Innate Pharma
11.14.1 Innate Pharma Corporation Information
11.14.2 Innate Pharma Overview
11.14.3 Innate Pharma Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.14.4 Innate Pharma Immune Checkpoint Inhibitors Products and Services
11.14.5 Innate Pharma Recent Developments
11.15 Sorrento Therapeutics
11.15.1 Sorrento Therapeutics Corporation Information
11.15.2 Sorrento Therapeutics Overview
11.15.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.15.4 Sorrento Therapeutics Immune Checkpoint Inhibitors Products and Services
11.15.5 Sorrento Therapeutics Recent Developments
11.16 GlaxoSmithKline
11.16.1 GlaxoSmithKline Corporation Information
11.16.2 GlaxoSmithKline Overview
11.16.3 GlaxoSmithKline Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.16.4 GlaxoSmithKline Immune Checkpoint Inhibitors Products and Services
11.16.5 GlaxoSmithKline Recent Developments
11.17 GITR, Inc
11.17.1 GITR, Inc Corporation Information
11.17.2 GITR, Inc Overview
11.17.3 GITR, Inc Immune Checkpoint Inhibitors Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.17.4 GITR, Inc Immune Checkpoint Inhibitors Products and Services
11.17.5 GITR, Inc Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Immune Checkpoint Inhibitors Value Chain Analysis
12.2 Immune Checkpoint Inhibitors Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Immune Checkpoint Inhibitors Production Mode & Process
12.4 Immune Checkpoint Inhibitors Sales and Marketing
12.4.1 Immune Checkpoint Inhibitors Sales Channels
12.4.2 Immune Checkpoint Inhibitors Distributors
12.5 Immune Checkpoint Inhibitors Customers
13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
  • FORMAT: PDF
  • PUBLISHED DATE: Mar, 2021
  • NO OF PAGES: 101